BIS executives are confident as they trade today (5/5) with a satisfactory response. It is the first vaccine and veterinary drug stock in the Thai stock market, confident in continuous business growth and preparing to expand operations in both livestock and pet sectors, starting with dog and cat food sales from renowned brands to boost sales significantly.

 

Dr. Thanawat Kongjaroensombat, CEO of Bioscience Animal Health Public Company Limited (BIS), stated that he is confident that BIS's IPO stock will receive a positive response from investors after high interest during the roadshow and stock subscription. After fundraising, existing shareholders will hold approximately 70% of the shares, with the original shares of the board and executives under a silent period totaling 55%, according to the SEC's criteria. In 2021, BIS's net profit grew significantly to 69 million baht from 54 million baht in 2020, and total revenue increased to 1,987 million baht from 1,784 million baht in 2020.

Despite facing the COVID-19 pandemic and African swine fever (ASF), which directly impacted the livestock industry, BIS has several strengths, such as being a leading importer of global vaccines, drugs, and pharmaceuticals from various manufacturers, having a large customer base nationwide, and being able to innovate solutions for global hygiene issues, such as producing COVID-19 test kits using Real-time PCR, the first Thai manufacturer certified by the Ministry of Public Health, and producing ASF test kits, both of which have received high market acceptance with rapid and continuous sales growth.

 

Currently, approximately 80% of the company's revenue comes from the livestock industry, which is the upstream business of the food industry, with an export value exceeding 1,200,000 baht (excluding domestic consumption) in 2022. About 20% of revenue comes from the pet-related business, which is experiencing high growth. The company expects to benefit from Thailand reopening, leading to increased consumption of food and meat, as well as increased food exports. Meanwhile, the company has seen revenue from ASF test kits grow tenfold due to proactive testing policies from major private sector clients, large and small farms in 2021, and expects continued growth this year, along with veterinary drugs, vaccines, and pharmaceuticals for pets, which will expand in line with the recovering Thai economy. The company plans to invest in producing its own brand products to increase revenue from nutrition products and vitamins for animals and to further invest in developing vaccines for animals for sale in Thailand and the ASEAN region, replacing imports from abroad.

 

In the pet market, BIS has signed a distribution agreement for global dog food brand Pedigree and cat food brand Cesar with Mars (Thailand) Co., Ltd. since January this year, focusing on the market in over 1,000 veterinary hospitals and clinics nationwide, expecting a positive response. Regarding total revenue, management believes that total revenue will continue to grow due to the improving Thai and global economies. The reopening of the country will help increase meat production and consumption, while revenue from animal disease test kits is expected to continue growing as they are essential for farms to prevent disease outbreaks. Additionally, BIS is supported by the pet business, with expected significant sales growth from the Pedigree and Cesar brands. With all these factors, management aims for total revenue to grow continuously from 2021 by no less than 20%.

 

The Bioscience group or “BIS” owns various brands of veterinary pharmaceuticals, with its own manufacturing facility meeting international standards. The company offers a comprehensive range of animal health products: 1. Animal health products for treatment and prevention, 2. Nutrition products and vitamins for animals, 3. Diagnostic products for animals, 4. Complete feed products for animals, 5. Ingredient products for animal feed, and 6. Other products. The company has a large customer base in Thailand's food industry, which has a high export value ranking globally, as Thailand is one of the world's kitchens.

 

Mr. Prasert Tantayawit, Managing Director of Investment Banking at Maybank Securities (Thailand) Public Company Limited, as the financial advisor for the registration in the MAI stock market and the underwriter for the public offering of Bioscience Animal Health Public Company Limited, stated, “I am confident that BIS shares will attract interest from both long-term investors and retail investors, as BIS has a strong business foundation and high growth potential. The company is in the biotech sector, which is one of the government’s New S-Curve industries. Additionally, BIS has extensive business management experience and excellent relationships with numerous customers and business partners, both Thai and international. Furthermore, BIS is in the pharmaceutical, vaccine, and veterinary product industry, which is a crucial piece of the puzzle in Thailand's food industry, which is significant and highly valued, thus having the opportunity to grow continuously alongside Thailand's food industry, which has a high global food export value.

 

BIS has raised funds by selling 94 million new ordinary shares to the public for the first time (IPO) at a price of 6.00 baht per share (par value of 0.50 baht), representing 29.94% of the registered capital after the IPO, amounting to approximately 564 million baht, and is scheduled to start trading on the MAI stock market on May 5, 2022.

 

Business Overview of Bioscience Animal Health Public Company Limited (BIS)

Bioscience Animal Health Public Company Limited (BIS) is a leader in comprehensive health care for livestock and pets, offering: 1. Animal health products for treatment and prevention, 2. Nutrition products and vitamins for animals, 3. Diagnostic products for animals, 4. Complete feed products for animals, 5. Ingredient products for animal feed, and 6. Other products. The company was established in 2004 with a registered capital of 157 million baht and paid-up capital of 110 million baht. The Bioscience Animal Health group is committed to being a valuable business partner with products, services, technology, and innovations related to animals. The company plans to offer 94 million shares (par 0.50 baht) to the general public and register on the mai stock market, preparing to become one of the leading biotech companies in Thailand and the ASEAN region, growing sustainably in the ASEAN region.